A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
← catalyst calendarSponsored by Atara Biotherapeutics (industry) · ATRA — their whole pipeline →.
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
0actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Financial
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-16 | actual | When the study began enrolling |
| Primary completion | 2025-04-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-04-16 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lupus Nephritis
- Systemic Lupus Erythematosus
Intervention
- Drug: ATA3219
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With treatment-emergent adverse events, including adverse events of special interest
measured From administration of pretreatments (LD or methylprednisolone) through 90 days after administration of study drug
Number of Participants With Dose-limiting Toxicities
measured Day 1 through Day 28 of first dose of study drug
Maximum Tolerated dose
measured Day 1 through Day 28 of first dose of study drug
Recommended Phase 2 dose of ATA3219
measured Day 1 through Day 28 of first dose of study drug
Publications
- PMID 22553077 — cited as background
- PMID 19213865 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ATRA's whole pipeline · Catalyst calendar · Every registered study · What changed